Quick Comparison

TB-500TB-500 + BPC-157 + GHK-Cu
Half-Life2-3 hoursBPC-157: 4 hours | TB-500: 2-3 hours | GHK-Cu: 1-2 hours
Typical DosageLoading: 2-5 mg subcutaneous twice weekly for 4-6 weeks. Maintenance: 2-5 mg subcutaneous every 2 weeks. Some protocols use daily dosing during acute injury phase.Varies by supplier formulation. Typical: combined dose subcutaneous two or three times weekly for 4-8 weeks. Individual component doses are generally lower than standalone use due to synergistic effects.
AdministrationSubcutaneous or intramuscular injectionSubcutaneous injection
Research Papers2 papers2 papers
Categories

Mechanism of Action

TB-500

TB-500 is the active fragment of Thymosin Beta-4 (Tβ4), a 43-amino-acid peptide present in virtually every nucleated cell in the body. Its central molecular function is the sequestration of G-actin monomers — the globular, unpolymerized form of actin. By binding G-actin at a 1:1 ratio, TB-500 maintains a reservoir of monomeric actin that can be rapidly mobilized for polymerization into F-actin filaments when cells need to migrate, change shape, or form new structures during tissue repair.

This actin-regulating role is fundamental to TB-500's healing effects. When tissue is damaged, cells at the wound margin must migrate into the injury site. Cell migration requires dynamic actin polymerization at the leading edge of the cell (forming lamellipodia and filopodia) and depolymerization at the trailing edge. TB-500 facilitates this process by providing a controlled supply of G-actin monomers. It promotes migration of keratinocytes (for skin wound closure), endothelial cells (for new blood vessel formation), and cardiac progenitor cells (for heart repair).

Beyond actin regulation, TB-500 has significant anti-inflammatory and gene-regulatory effects. It downregulates pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α while upregulating anti-inflammatory mediators. It activates cell survival pathways, specifically Akt-mediated anti-apoptotic signaling, protecting damaged cells from programmed cell death. TB-500 also promotes angiogenesis by stimulating endothelial progenitor cell differentiation and new capillary formation. In cardiac tissue, it has demonstrated the ability to activate epicardial progenitor cells and promote cardiomyocyte survival following ischemic injury. The combination of cell migration, anti-inflammation, angiogenesis, and cell survival makes TB-500 one of the most broad-spectrum healing peptides available.

TB-500 + BPC-157 + GHK-Cu

This triple combination adds the copper peptide GHK-Cu to the BPC-157/TB-500 healing stack, introducing a third distinct mechanism — copper-dependent enzymatic tissue remodeling — alongside the NO/growth factor signaling of BPC-157 and the actin-mediated cell migration of TB-500.

GHK-Cu contributes uniquely through its ability to deliver bioavailable copper to cells and activate copper-dependent enzymes. Lysyl oxidase, a copper-dependent enzyme, catalyzes the cross-linking of collagen and elastin fibers, which is essential for creating organized, structurally sound connective tissue rather than disorganized scar tissue. Superoxide dismutase (SOD), another copper-dependent enzyme, provides antioxidant defense at the wound site, protecting newly forming tissue from oxidative damage. GHK-Cu also stimulates the synthesis of collagen types I and III, elastin, glycosaminoglycans, and decorin — the fundamental building blocks of the extracellular matrix.

The theoretical three-layer synergy works as follows: TB-500 acts first by mobilizing repair cells through actin regulation and reducing acute inflammation. BPC-157 creates the vascular and biochemical infrastructure for repair through angiogenesis and growth factor upregulation. GHK-Cu then supports the remodeling phase — the final stage of wound healing where disorganized early repair tissue is replaced with properly structured, functional tissue. GHK-Cu's gene-regulatory effects (modulating expression of over 4,000 genes) may also amplify the effects of the other two peptides by creating a favorable transcriptional environment for regeneration. As with the dual BPC/TB stack, no clinical data exists for this specific triple combination.

Risks & Safety

TB-500

Common

headaches, nausea, fatigue, injection site irritation, temporary lightheadedness.

Serious

may promote growth of existing cancerous cells by stimulating cell movement and new blood vessel growth; theoretical risk of speeding up undetected tumors.

Rare

allergic reactions, localized infection.

TB-500 + BPC-157 + GHK-Cu

Common

injection site irritation, nausea, headache, temporary fatigue.

Serious

theoretical risk of promoting existing tumors since all three peptides stimulate cell growth and new blood vessel formation; no data on interactions between three bioactive compounds used together.

Rare

allergic reactions, copper-related effects from the GHK-Cu component.

Full Profiles